A Training Set for the HRD Model in EOC

A Training Set for the Homologous Recombination Deficiency Scoring Model With Loss of Heterozygosity Status in Epithelial Ovarian Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04651933

Enrollment

200

Registered

2020-12-03

Start date

2020-11-26

Completion date

2022-11-26

Last updated

2020-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BRCA Mutation, Epithelial Ovarian Cancer, Homologous Recombination Deficiency, Loss of Heterozygosity, Platinum Resistance, Prognosis

Brief summary

A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH) is little explored in epithelial ovarian cancer (EOC) patients. This study would recruit 200 Chinese EOC patients with known BRCA1/2 mutation status and resistance to platinum-based chemotherapy. A LOH-HRD model is to be constructed based on the genetic testing in these patients. The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients, and a potential explanation of platinum-resistance in such population.

Interventions

GENETICHomologous recombination deficiency model

A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Aged 18 years or older * Pathological confirmation of epithelial ovarian cancer * With available tumor tissues * Given consents to participate the study

Exclusion criteria

• Not meeting all of the inclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Homologous recombination deficiency (HRD) score	Two years	The HRD score for individual patient is a scale describing her HRD status. The score model is calculated by the analysis for loss of heterozygosity (LOH), and the minimum value is 0, but the maximun value is not available. Higher scores mean more sensitivity to poly-ADP-ribose polymerase inhibitor

Secondary

Measure	Time frame	Description
Progression-free survival	Five years	Progression-free survival in recruited patients
Overall survival	Five years	Overall survival in recruited patients

Countries

China

Contacts

Primary ContactLei Li, M.D.

lileigh@163.com+8613911988831

Backup ContactMing Wu, M.D.

wuming@pumch.cn+8613810224549

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026